October 2021 with special guest Nicholas DeVito

In this episode Jamie Hartmann-Boyce and Nicola Lindson discuss the emerging evidence in e-cigarette research and interview Nicholas DeVito. This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches.

In the October 2021 episode Jamie Hartmann-Boyce talks with Nick DeVito from the Evidence Based DataLab at the University of Oxford. They discuss his recent research which looks at e-cigarette manufacturers' compliance with clinical trial reporting expectations focussing on trials by Juul Labs and how they report their data. Nick's study was published in BMJ Tobacco Control (http://dx.doi.org/10.1136/tobaccocontrol-2020-056221). The discussion covered the importance of whether, where and how research findings are reported or published including publication bias and reporting bias, the selective reporting of outcomes. This interview covers the crucial role of trial registration for research transparency. Nick describes the FDA amendment act, in which studies are registered within 21 days with pre-registered outcomes and a primary completion date and that the results are to be put onto clinicaltrials.gov within a year. Clinicians, public health professionals, and the public cannot make informed choices about the benefits or hazards of e-cigarettes if the results of clinical trials are not completely and transparently reported. This interview highlights that transparency is key and the importance of all evidence being made available.

For more information on the September Cochrane review see: https://doi.org/10.1002/14651858.CD010216.pub6 or our webpage.

Jamie and Nicola also bring us up to date with the literature search conducted on October 1st. The October search found one new included study two reports linked to studies already in the review, and one new ongoing (NCT04854616). The DOI for the new included study (Morris 2021) is https://doi.org/10.1007/s11739-021-02813-w. We will include the studies we've found in future updates of the Cochrane review.